Few & Far Between: How Biotech Gets Built

"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy that we used actually drew from all of my past experience in computational protein design and combined it with these incredible new organisms." - Dan Mandell, CEO at GRO Biosciences

Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Dan Mandell, CEO at GRO Biosciences, as they discuss the latest breakthroughs in protein design - from biocontainment to creating a new amino acid alphabet. 

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax

Biorasi is excited to welcome Stephanie Wisner to the Few & Far Between podcast. Stephanie is the author of "Building Backwards to Biotech: The Power of Entrepreneurship to Drive Cutting-Edge Science to Market." Join host Chris O'Brien as we explore the multitude of opportunities and pitfalls in today's biotech industry.

Stephanie's book is availabe on Amazaon at https://a.co/d/4afgMpR 

"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condition and they know more about the everyday kind of what they go through than their doctor even would because they're not with them 24/7." - Pam Cusick, SVP, Rare Patient Voice

Biorasi's Marc Gas welcomes Pam Cusick, SVP at Rare Patient Voice, to the Few & Far Between podcast for an episode focusing on the power of rare patient input across the clinical trials industry.

Connect with Rare Patient Voice on the road in 2023 at:

UXPA International - Austin, TX - June 20-22
DIA - Boston, MA - June 26-28
Global Genes - San Diego, CA - September 19-21

"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that indicate that there may be hope for that patient, we should do something to hear the voice of that patient and learn." - Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH

Welcome back to part two of our conversation with Dr. Francisco Harrison. Join us in this Few & Far Between episode as we dive deeper to discuss new opportunities, new responsibilities, and new experiences...including walking the 500-mile Camino trail from France to the Santiago de Compostela in Spain.

"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH

Biorasi welcomes Dr. Francisco Harrison to the Few and Far Between podcast for a special two-part episode. In part one, we track Dr. Harrison's origin story - from medical school to his first forays into clinical research.

"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the future and providing them and their physicians with decision support and alternative thinking about ways to treat their cancer." Mika Newton, CEO at xCures

Biorasi welcomes Mika Newton to the Few & Far Between podcast to examine how the connection between AI and oncology leads to a more patient-centric world.

“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other families who have sick kids is that we all have a tremendous amount of hope that a potential treatment will come to the forefront for our child.” – Dr. Alok Tayi, Founder and CEO of Vibe Bio

Biorasi welcomes Dr. Alok Tayi to the Few & Far Between podcast to explore the power and determination that patients have when it comes to finding a treatment for rare disease. 

"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific

Welcome back to Part 2 of our special Few & Far Between podcast episode with guest, Jamie Heywood. Continuing our discussion on the role of engineering in clinical research - and making the world a better place for people - we'll explore the path to innovation, including data tracking strategies and securing project funding.

"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of engineering." - Jamie Heywood, CEO at Alden Scientific

Biorasi welcomes Jamie Heywood to the Few & Far Between podcast to discuss the critical role engineering plays in clinical research.